Changes in type-specific human papillomavirus load predict progression to cervical cancer

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 12, 2012, Pages 3096-3104

  Depuydt, Christophe E ^a   Criel, Arnold M ^a   Benoy, Ina H ^a   Arbyn, Marc ^b   Vereecken, Annie J ^a   Bogers, Johannes J ^a,c  

^a Sonic Healthcare Benelux   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cervical intraepithelial neoplasia; Liquid based cytology leftover; Real time quantitative PCR; Viral doubling time; Virologic model

Indexed keywords

ONCOPROTEIN; VIRUS DNA;

ARTICLE; CLASSIFICATION; COHORT ANALYSIS; FEMALE; GENETICS; HUMAN; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84870739724     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01631.x     Document Type: Article

References (31)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-65.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
3. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999; 354: 20-5.
4. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007; 7: 11-22.
5. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007; 212: 356-67.
6. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24: S3-78-S3/89.
7. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-101.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11: 249-57.
9. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004; 112: 854-9.
10. Ho CM, Chien TY, Huang SH, et al. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol. 2006; 102: 54-60.
11. Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev. 2010; 19: 832-7.
12. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007; 121: 2787-93.
13. Xi LF, Hughes JP, Castle PE, et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis. 2011; 203: 1425-33.
14. Xi LF, Hughes JP, Edelstein ZR, et al. Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis. 2009; 200: 1789-97.
15. Van DM, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer. 2002; 98: 590-5.
16. Monnier-Benoit S, Dalstein V, Riethmuller D, et al. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol. 2006; 35: 270-7.
17. Marks M, Gravitt PE, Utaipat U, et al. Kinetics of DNA load predict HPV 16 viral clearance. J Clin Virol. 2011; 51: 44-9.
18. Boulet GA, Benoy IH, Depuydt CE, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or=2 in a liquid-based cytology setting? Cancer Epidemiol Biomarkers Prev. 2009; 18: 2992-9.
19. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100: 513-7.
20. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102: 1478-88.
21. Chen HC, Schiffman M, Lin CY, et al. Persistence of Type-Specific Human Papillomavirus Infection and Increased Long-term Risk of Cervical Cancer. J Natl Cancer Inst. 2011; 103: 1387-96.
22. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006; 66: 10630-6.
23. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007; 195: 1582-9.
24. Benoy IH. Vanden Broeck D, Ruymbeke MJ et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol. 2011; 205(569): e1-7.
25. Jordan J, Martin-Hirsch P, Arbyn M, et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology. 2009; 20: 5-16.
26. Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008; 19: 342-54.
27. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology. 2007; 18: 133-9.
28. Depuydt CE, Benoy IH, Bailleul EJ, et al. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology. 2006; 17: 374-81.
29. Micalessi I, Boulet GA, Bogers JJ, et al. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med. 2011; 50: 655-61.
30. Schoonjans F, Zalata A, Depuydt CE, et al. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995; 48: 257-62.
31. Depuydt CE, Boulet GA, Horvath CA, et al. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med. 2007; 11: 881-91.